DK1274692T3 - Quinazolinforbindelser - Google Patents

Quinazolinforbindelser

Info

Publication number: DK1274692T3
Authority: DK; Denmark
Prior art keywords: sup; aromatic; ring; saturated; psorlasis
Prior art date: 2000-04-07

Application number

DK01921530T

Other languages

Danish (da)

English (en)

Inventor

Laurent Francois And Hennequin

Elaine Sophie Elizabeth Stokes

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-07

Filing date

2001-04-03

Publication date

2006-10-30

2001-04-03 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2006-10-30 Application granted granted Critical

2006-10-30 Publication of DK1274692T3 publication Critical patent/DK1274692T3/da

Links

JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1
125000003118 aryl group Chemical group 0.000 abstract 2
229920006395 saturated elastomer Polymers 0.000 abstract 2
125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
241001465754 Metazoa Species 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
230000001772 anti-angiogenic effect Effects 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
125000005842 heteroatom Chemical group 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 abstract 1
230000001603 reducing effect Effects 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
230000008728 vascular permeability Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Surgery (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Obesity (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK01921530T 2000-04-07 2001-04-03 Quinazolinforbindelser DK1274692T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP00400968		2000-04-07
EP00400967		2000-04-07
EP00401034		2000-04-13
EP00401033		2000-04-13

Publications (1)

Publication Number	Publication Date
DK1274692T3 true DK1274692T3 (da)	2006-10-30

Family

ID=27440054

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01921530T DK1274692T3 (da)	2000-04-07	2001-04-03	Quinazolinforbindelser

Country Status (20)

Country	Link
US (2)	US7160889B2 (de)
EP (1)	EP1274692B1 (de)
JP (2)	JP4970689B2 (de)
KR (1)	KR100858069B1 (de)
CN (1)	CN1240688C (de)
AT (1)	ATE334973T1 (de)
AU (1)	AU779695B2 (de)
BR (1)	BR0109828A (de)
CA (1)	CA2403365A1 (de)
CY (1)	CY1107539T1 (de)
DE (1)	DE60121931T2 (de)
DK (1)	DK1274692T3 (de)
ES (1)	ES2267748T3 (de)
IL (2)	IL151626A0 (de)
MX (1)	MXPA02009891A (de)
NO (1)	NO324471B1 (de)
NZ (1)	NZ521421A (de)
PT (1)	PT1274692E (de)
SI (1)	SI1274692T1 (de)
WO (1)	WO2001077085A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EE04748B1 (et) *	1999-06-21	2006-12-15	Boehringer Ingelheim Pharma Kg	Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetodid nende valmistamiseks
CZ301689B6 (cs)	1999-11-05	2010-05-26	Astrazeneca Ab	Derivát chinazolinu a farmaceutický prostredek, který ho obsahuje
AU2001235804A1 (en)	2000-03-06	2001-09-17	Astrazeneca Ab	Therapy
UA73993C2 (uk)	2000-06-06	2005-10-17	Астразенека Аб	Хіназолінові похідні для лікування пухлин та фармацевтична композиція
CA2419301C (en)	2000-08-21	2009-12-08	Astrazeneca Ab	Quinazoline derivatives
US6849625B2 (en)	2000-10-13	2005-02-01	Astrazeneca Ab	Quinazoline derivatives with anti-tumour activity
WO2002030926A1 (en)	2000-10-13	2002-04-18	Astrazeneca Ab	Quinazoline derivatives
DE60144284D1 (de)	2000-11-01	2011-05-05	Millennium Pharm Inc	Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
US7019012B2 (en) *	2000-12-20	2006-03-28	Boehringer Ingelheim International Pharma Gmbh & Co. Kg	Quinazoline derivatives and pharmaceutical compositions containing them
DE60229046D1 (de)	2001-04-19	2008-11-06	Astrazeneca Ab	Chinazolin derivate
JP4608215B2 (ja) *	2002-02-01	2011-01-12	アストラゼネカアクチボラグ	キナゾリン化合物
US6924285B2 (en)	2002-03-30	2005-08-02	Boehringer Ingelheim Pharma Gmbh & Co.	Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
DE10221018A1 (de) *	2002-05-11	2003-11-27	Boehringer Ingelheim Pharma	Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
EP2280003B1 (de)	2002-07-15	2014-04-02	Symphony Evolution, Inc.	Verfahren zur Herstellung von Rezeptorkinase-Modulatoren
RU2350618C2 (ru)	2002-11-04	2009-03-27	Астразенека Аб	ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
AU2003292435A1 (en) *	2002-12-23	2004-07-14	Astrazeneca Ab	4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents
US7223749B2 (en) *	2003-02-20	2007-05-29	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
DE10326186A1 (de) *	2003-06-06	2004-12-23	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
GB0317665D0 (en)	2003-07-29	2003-09-03	Astrazeneca Ab	Qinazoline derivatives
GB0318423D0 (en) *	2003-08-06	2003-09-10	Astrazeneca Ab	Chemical compounds
ES2305844T3 (es)	2003-09-16	2008-11-01	Astrazeneca Ab	Derivados de quinazolina como inhibidores de tirosina cinasa.
GB0322409D0 (en)	2003-09-25	2003-10-29	Astrazeneca Ab	Quinazoline derivatives
US7456189B2 (en)	2003-09-30	2008-11-25	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
GB0326459D0 (en)	2003-11-13	2003-12-17	Astrazeneca Ab	Quinazoline derivatives
EP1723129A1 (de) *	2003-12-18	2006-11-22	Cv Therapeutics, Inc.	1-alkan-2-ol-substituierte piperazin- und piperidinverbindungen
JP4934432B2 (ja) *	2004-02-19	2012-05-16	レクサンファーマシューティカルズインコーポレイテッド	キナゾリン誘導体およびキナゾリン誘導体の治療への使用
EP1734040A4 (de) *	2004-03-23	2007-11-28	Banyu Pharma Co Ltd	Substituiertes chinazolin- oder pyridopyrimidinderivat
CN1972688B (zh)	2004-05-06	2012-06-27	沃尼尔·朗伯有限责任公司	4-苯胺基-喹唑啉-6-基-酰胺类化合物
US7285569B2 (en)	2004-09-24	2007-10-23	Hoff Hoffmann-La Roche Inc.	Tricycles, their manufacture and use as pharmaceutical agents
TW200624431A (en)	2004-09-24	2006-07-16	Hoffmann La Roche	Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
US7462639B2 (en)	2005-04-14	2008-12-09	Hoffmann-La Roche Inc.	Aminopyrazole derivatives
US7732613B2 (en)	2005-09-14	2010-06-08	Bristol-Myers Squibb Company	Met kinase inhibitors
CA2833706C (en)	2005-11-11	2014-10-21	Boehringer Ingelheim International Gmbh	Quinazoline derivatives for the treatment of cancer diseases
AU2007299080B2 (en) *	2006-09-18	2013-04-18	Boehringer Ingelheim International Gmbh	Method for treating cancer harboring EGFR mutations
EP1921070A1 (de)	2006-11-10	2008-05-14	Boehringer Ingelheim Pharma GmbH & Co. KG	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
EP2118075A1 (de)	2007-02-06	2009-11-18	Boehringer Ingelheim International GmbH	Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
US20080190689A1 (en) *	2007-02-12	2008-08-14	Ballard Ebbin C	Inserts for engine exhaust systems
CA2711582A1 (en)	2008-02-07	2009-08-13	Boehringer Ingelheim International Gmbh	Spirocyclic heterocycles, formulations containing said compounds, use thereof and processes for the preparation thereof
EP2303276B1 (de)	2008-05-13	2013-11-13	AstraZeneca AB	Fumarat salz von 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}chinazolin
CA2733153C (en)	2008-08-08	2016-11-08	Boehringer Ingelheim International Gmbh	Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
PL2451445T3 (pl)	2009-07-06	2019-09-30	Boehringer Ingelheim International Gmbh	Sposób suszenia BIBW2992, jego soli i stałych preparatów farmaceutycznych zawierających tę substancję czynną
CN102060875B (zh) *	2009-11-18	2014-03-12	天津药物研究院	喹唑啉衍生物、制备方法和用途
US9242965B2 (en)	2013-12-31	2016-01-26	Boehringer Ingelheim International Gmbh	Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CN105153047A (zh) *	2015-08-25	2015-12-16	佛山市赛维斯医药科技有限公司	含新型苯并喹唑啉和邻位氟结构的酪氨酸激酶抑制剂及用途
KR20180086187A (ko)	2015-10-05	2018-07-30	더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕	자가포식 유동의 활성체 및 포스포리파제 d 및 타우를 포함하는 단백질 응집물의 클리어런스 및 단백질질환의 치료
CN106083836B (zh) *	2016-06-26	2021-08-20	徐州医学院	基于喹唑啉结构的h2s供体化合物及其应用

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE317376B (de)	1961-07-10	1969-11-17	Roussel Uclaf
US3266990A (en)	1963-09-24	1966-08-16	Warner Lambert Pharmaceutical	Derivatives of quinazoline
FR2077455A1 (en)	1969-09-03	1971-10-29	Aries Robert	5-haloveratryl-4-aminoquinoles - antimalarials amoebicides anthelmintics anticoccidials
US3870725A (en)	1971-03-30	1975-03-11	Lilly Industries Ltd	Nitrothiazole derivatives
JPS542327A (en)	1977-06-07	1979-01-09	Sankyo Co Ltd	Agricultural and horticultural pesticide
JPS5538325A (en)	1978-09-11	1980-03-17	Sankyo Co Ltd	4-anilinoquinazoline derivative and its preparation
US4343940A (en)	1979-02-13	1982-08-10	Mead Johnson & Company	Anti-tumor quinazoline compounds
FR2498187A1 (fr)	1981-01-16	1982-07-23	Rhone Poulenc Sante	Procede de preparation d'amino-4 chloro-7 quinoleines
GB2160201B (en)	1984-06-14	1988-05-11	Wyeth John & Brother Ltd	Quinazoline and cinnoline derivatives
IL81307A0 (en)	1986-01-23	1987-08-31	Union Carbide Agricult	Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives
ATE110071T1 (de)	1988-01-23	1994-09-15	Kyowa Hakko Kogyo Kk	Pyridazinon-derivate und diese enthaltende pharmazeutische zubereitungen.
US5411963A (en)	1988-01-29	1995-05-02	Dowelanco	Quinazoline derivatives
IL89029A (en)	1988-01-29	1993-01-31	Lilly Co Eli	Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
CZ387292A3 (en)	1991-02-20	1994-04-13	Pfizer	2,4-diaminoquinazoline derivatives, process of their preparation and use as substances for increasing anti-tumorous activity
AU1422392A (en)	1991-03-22	1992-10-21	Nippon Soda Co., Ltd.	2-substituted pyridine derivative, production thereof, and agrohorticultural bactericide
US5409930A (en)	1991-05-10	1995-04-25	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en)	1991-05-10	1998-01-20	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en)	1991-05-10	1998-02-24	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5480883A (en)	1991-05-10	1996-01-02	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5714493A (en)	1991-05-10	1998-02-03	Rhone-Poulenc Rorer Pharmaceuticals, Inc.	Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
NZ243082A (en)	1991-06-28	1995-02-24	Ici Plc	4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
FI940469L (fi)	1991-08-02	1994-02-01	Pfizer	Kinoliinijohdannaisia immunostimulantteina
GB9127252D0 (en)	1991-12-23	1992-02-19	Boots Co Plc	Therapeutic agents
AU661533B2 (en)	1992-01-20	1995-07-27	Astrazeneca Ab	Quinazoline derivatives
DE4208254A1 (de)	1992-03-14	1993-09-16	Hoechst Ag	Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid
US5270466A (en)	1992-06-11	1993-12-14	American Cyanamid Company	Substituted quinazoline fungicidal agents
JP2994165B2 (ja) *	1992-06-26	1999-12-27	ゼネカ・リミテッド	キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
US5792771A (en)	1992-11-13	1998-08-11	Sugen, Inc.	Quinazoline compounds and compositions thereof for the treatment of disease
US5712395A (en)	1992-11-13	1998-01-27	Yissum Research Development Corp.	Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US6177401B1 (en)	1992-11-13	2001-01-23	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften	Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en)	1992-12-10	1994-01-05	Zeneca Ltd	Quinazoline derivatives
GB9314893D0 (en)	1993-07-19	1993-09-01	Zeneca Ltd	Quinazoline derivatives
GB9314884D0 (en)	1993-07-19	1993-09-01	Zeneca Ltd	Tricyclic derivatives
US5656643A (en)	1993-11-08	1997-08-12	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5700823A (en)	1994-01-07	1997-12-23	Sugen, Inc.	Treatment of platelet derived growth factor related disorders such as cancers
BR9506936A (pt)	1994-02-23	1997-09-09	Pfizer	Derivados de quinazolina substituídos com 4-heterociclila processos para sua preparaçao e seu uso como agentes anticancerosos
WO1995024190A2 (en)	1994-03-07	1995-09-14	Sugen, Inc.	Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9510757D0 (en)	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
TW321649B (de)	1994-11-12	1997-12-01	Zeneca Ltd
GB9424233D0 (en)	1994-11-30	1995-01-18	Zeneca Ltd	Quinazoline derivatives
AU5108196A (en)	1995-03-20	1996-10-08	Dr. Karl Thomae Gmbh	Imidazoquinazolines, drugs containing these compounds, their use and process for their preparation
IL117620A0 (en)	1995-03-27	1996-07-23	Fujisawa Pharmaceutical Co	Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same
MX9707453A (es)	1995-03-30	1997-12-31	Pfizer	Derivados de quinazolina.
GB9508535D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivative
GB9508537D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
GB9508538D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
WO1996033977A1 (en)	1995-04-27	1996-10-31	Zeneca Limited	Quinazoline derivatives
GB9508565D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quiazoline derivative
TW334434B (en)	1995-05-16	1998-06-21	Kanebo Ltd	Novel quinazoline compound and anti-tumor agent
US5747498A (en)	1996-05-28	1998-05-05	Pfizer Inc.	Alkynyl and azido-substituted 4-anilinoquinazolines
US5650415A (en)	1995-06-07	1997-07-22	Sugen, Inc.	Quinoline compounds
US5773459A (en)	1995-06-07	1998-06-30	Sugen, Inc.	Urea- and thiourea-type compounds
CA2222545A1 (en)	1995-06-07	1996-12-19	Sugen, Inc.	Quinazolines and pharmaceutical compositions
MX9800215A (es)	1995-07-06	1998-03-31	Novartis Ag	Pirrolopirimidas y procesos para su preparacion.
GB9514265D0 (en)	1995-07-13	1995-09-13	Wellcome Found	Hetrocyclic compounds
US6143764A (en)	1995-11-07	2000-11-07	Kirin Beer Kabushiki Kaisha	Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same
GB9624482D0 (en)	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
CH690773A5 (de)	1996-02-01	2001-01-15	Novartis Ag	Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
US5760041A (en)	1996-02-05	1998-06-02	American Cyanamid Company	4-aminoquinazoline EGFR Inhibitors
BR9707495A (pt)	1996-02-13	1999-07-27	Zeneca Ltd	Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
GB9603095D0 (en)	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
GB9603097D0 (en)	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline compounds
US6291455B1 (en) *	1996-03-05	2001-09-18	Zeneca Limited	4-anilinoquinazoline derivatives
EP0888310B1 (de)	1996-03-15	2005-09-07	AstraZeneca AB	Cinoline derivate und verwendung als heilmittel
AU5533996A (en)	1996-04-04	1997-10-29	University Of Nebraska Board Of Regents	Synthetic triple helix-forming compounds
HU228446B1 (en) *	1996-04-12	2013-03-28	Warner Lambert Co	Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
GB9607729D0 (en)	1996-04-13	1996-06-19	Zeneca Ltd	Quinazoline derivatives
DE19614718A1 (de)	1996-04-15	1997-10-16	Hoechst Schering Agrevo Gmbh	Substituierte Pyridine/Pyrimidine, Verfahren zu ihrer Herstellung, und ihre Verwendung als Schädlingsbekämpfungsmittel
GB9707800D0 (en)	1996-05-06	1997-06-04	Zeneca Ltd	Chemical compounds
GB9613021D0 (en)	1996-06-21	1996-08-28	Pharmacia Spa	Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
ID19609A (id)	1996-07-13	1998-07-23	Glaxo Group Ltd	Senyawa-senyawa heterosiklik
CA2265630A1 (en)	1996-09-13	1998-03-19	Gerald Mcmahon	Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
KR100567649B1 (ko)	1996-09-25	2006-04-05	아스트라제네카 유케이 리미티드	혈관 내피 성장 인자와 같은 성장 인자의 효과를 억제하는 퀴놀린 유도체
GB9718972D0 (en)	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
NZ330571A (en)	1996-10-01	1999-10-28	Kyowa Hakko Kogyo Kk	Nitrogenous heterocyclic compounds that may contain sulphur or oxygen
EP0837063A1 (de)	1996-10-17	1998-04-22	Pfizer Inc.	4-Aminoquinazolinderivate
US6413971B1 (en)	1996-11-27	2002-07-02	Pfizer Inc	Fused bicyclic pyrimidine derivatives
CO4950519A1 (es)	1997-02-13	2000-09-01	Novartis Ag	Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
UA73073C2 (uk)	1997-04-03	2005-06-15	Уайт Холдінгз Корпорейшн	Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en)	1997-04-03	1999-12-14	American Cyanamid Company	Substituted 3-cyano quinolines
ATE241986T1 (de)	1997-05-06	2003-06-15	Wyeth Corp	Verwendung von chinazolin verbindungen zur behandlung von polyzystischer nierenkrankheit
US5929080A (en)	1997-05-06	1999-07-27	American Cyanamid Company	Method of treating polycystic kidney disease
ZA986729B (en)	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitors of tyrosine kinases
ZA986732B (en)	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitiors of tyrosine kinases
TW436485B (en)	1997-08-01	2001-05-28	American Cyanamid Co	Substituted quinazoline derivatives
AR016817A1 (es)	1997-08-14	2001-08-01	Smithkline Beecham Plc	Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
WO1999010349A1 (en)	1997-08-22	1999-03-04	Zeneca Limited	Oxindolylquinazoline derivatives as angiogenesis inhibitors
US6184226B1 (en)	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
KR100860295B1 (ko)	1998-10-08	2008-09-25	아스트라제네카 아베	퀴나졸린 유도체
SK288365B6 (sk)	1999-02-10	2016-07-01	Astrazeneca Ab	Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy
DE19911509A1 (de) *	1999-03-15	2000-09-21	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CZ301689B6 (cs)	1999-11-05	2010-05-26	Astrazeneca Ab	Derivát chinazolinu a farmaceutický prostredek, který ho obsahuje
AU2001235804A1 (en)	2000-03-06	2001-09-17	Astrazeneca Ab	Therapy
GB0008269D0 (en)	2000-04-05	2000-05-24	Astrazeneca Ab	Combination chemotherapy
WO2002012226A1 (en)	2000-08-09	2002-02-14	Astrazeneca Ab	Quinoline derivatives having vegf inhibiting activity
CA2416525A1 (en)	2000-08-09	2002-02-14	Astrazeneca Ab	Indole, azaindole and indazole derivatives having vegf inhibiting activity
ES2317923T3 (es)	2000-08-09	2009-05-01	Astrazeneca Ab	Compuestos de cinolina.
GB0126879D0 (en)	2001-11-08	2002-01-02	Astrazeneca Ab	Combination therapy
JP4608215B2 (ja)	2002-02-01	2011-01-12	アストラゼネカアクチボラグ	キナゾリン化合物
KR20050056190A (ko)	2002-08-09	2005-06-14	아스트라제네카 아베	암의 치료에서의 방사선 요법과 함께 혈관 내피 성장 인자수용체의 억제제인 ｚｄ6474의 병행 치료
GB0218526D0 (en)	2002-08-09	2002-09-18	Astrazeneca Ab	Combination therapy
GB0223380D0 (en)	2002-10-09	2002-11-13	Astrazeneca Ab	Combination therapy
PT1592423E (pt)	2003-02-13	2011-06-16	Astrazeneca Ab	Terapia de combinação de zd6474 com 5-fu e/ou cpt-11

2001
- 2001-04-03 ES ES01921530T patent/ES2267748T3/es not_active Expired - Lifetime
- 2001-04-03 DK DK01921530T patent/DK1274692T3/da active
- 2001-04-03 AT AT01921530T patent/ATE334973T1/de not_active IP Right Cessation
- 2001-04-03 NZ NZ521421A patent/NZ521421A/en unknown
- 2001-04-03 KR KR1020027013364A patent/KR100858069B1/ko not_active Expired - Fee Related
- 2001-04-03 JP JP2001575560A patent/JP4970689B2/ja not_active Expired - Fee Related
- 2001-04-03 SI SI200130631T patent/SI1274692T1/sl unknown
- 2001-04-03 DE DE60121931T patent/DE60121931T2/de not_active Expired - Lifetime
- 2001-04-03 WO PCT/GB2001/001514 patent/WO2001077085A1/en not_active Ceased
- 2001-04-03 EP EP01921530A patent/EP1274692B1/de not_active Expired - Lifetime
- 2001-04-03 US US10/240,658 patent/US7160889B2/en not_active Expired - Fee Related
- 2001-04-03 MX MXPA02009891A patent/MXPA02009891A/es active IP Right Grant
- 2001-04-03 BR BR0109828-4A patent/BR0109828A/pt not_active IP Right Cessation
- 2001-04-03 PT PT01921530T patent/PT1274692E/pt unknown
- 2001-04-03 CA CA002403365A patent/CA2403365A1/en not_active Abandoned
- 2001-04-03 CN CNB018106846A patent/CN1240688C/zh not_active Expired - Fee Related
- 2001-04-03 IL IL15162601A patent/IL151626A0/xx active IP Right Grant
- 2001-04-03 AU AU48507/01A patent/AU779695B2/en not_active Ceased
2002
- 2002-09-05 IL IL151626A patent/IL151626A/en not_active IP Right Cessation
- 2002-10-03 NO NO20024763A patent/NO324471B1/no not_active IP Right Cessation
2006
- 2006-11-01 CY CY20061101562T patent/CY1107539T1/el unknown
- 2006-11-17 US US11/600,752 patent/US20070066633A1/en not_active Abandoned
2012
- 2012-02-23 JP JP2012037026A patent/JP2012136537A/ja active Pending

Also Published As

Publication number	Publication date
ATE334973T1 (de)	2006-08-15
JP2003530387A (ja)	2003-10-14
BR0109828A (pt)	2002-12-17
DE60121931D1 (de)	2006-09-14
SI1274692T1 (sl)	2006-12-31
CN1240688C (zh)	2006-02-08
US20030191308A1 (en)	2003-10-09
MXPA02009891A (es)	2003-03-27
EP1274692B1 (de)	2006-08-02
US7160889B2 (en)	2007-01-09
JP2012136537A (ja)	2012-07-19
CY1107539T1 (el)	2013-03-13
US20070066633A1 (en)	2007-03-22
WO2001077085A1 (en)	2001-10-18
NO20024763L (no)	2002-11-19
ES2267748T3 (es)	2007-03-16
NZ521421A (en)	2004-09-24
IL151626A0 (en)	2003-04-10
AU4850701A (en)	2001-10-23
EP1274692A1 (de)	2003-01-15
PT1274692E (pt)	2006-11-30
CN1433405A (zh)	2003-07-30
KR20020084295A (ko)	2002-11-04
KR100858069B1 (ko)	2008-09-22
NO20024763D0 (no)	2002-10-03
IL151626A (en)	2008-06-05
AU779695B2 (en)	2005-02-10
CA2403365A1 (en)	2001-10-18
NO324471B1 (no)	2007-10-29
JP4970689B2 (ja)	2012-07-11
DE60121931T2 (de)	2007-03-01

Publication	Publication Date	Title
DE60121931D1 (de)	2006-09-14	Chinazolinverbindungen
FI913478A0 (fi)	1991-07-18	Diazinderivat.
DE60322267D1 (de)	2008-08-28	Chinolinderivate als glucokinase liganden
ATE296826T1 (de)	2005-06-15	Pyrazolo(1,5)pyridinderivate
IS6658A (is)	2002-12-17	Ný efnasambönd
NO20025792D0 (no)	2002-12-02	Kinazolinderivater for behandling av tumorer
DK0790986T3 (da)	1999-09-13	Anilinderivater
DE69918422D1 (de)	2004-08-05	Phthalazinone pde iii/iv hemmer
ATE316083T1 (de)	2006-02-15	Adamantanderivate
NO20023934D0 (no)	2002-08-19	Nye forbindelser
ES2243579T3 (es)	2005-12-01	Derivados de pirazolopirideno.
BG103399A (en)	2000-01-31	New heterocycle-substituted benzamides and their application for the treatment of diseases
BR0209149A (pt)	2004-07-13	Ftalazinonas
ATE341545T1 (de)	2006-10-15	Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase
ATE409185T1 (de)	2008-10-15	Chinazolin derivate
ATE311389T1 (de)	2005-12-15	Wirkstoffvorläufer von imidazopyridin-derivaten
SE0003476D0 (sv)	2000-09-28	Compounds
DE60108626D1 (de)	2005-03-03	Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
DE60131968D1 (de)	2008-01-31	PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
ES2104174T3 (es)	1997-10-01	Derivados de bencilamino, bencilamido y bencilimido ciclicos utilizados como agentes antipsicoticos.
ATE274513T1 (de)	2004-09-15	Verbindungen und verfahren zur behandlung von schmerz
CY1106472T1 (el)	2012-01-25	Η χρηση των παραγωγων υδροξυπυριδονης στην επουλωση πληγων
DE60305520D1 (de)	2006-06-29	2" oxo-voruscharin und derivaten